Sales hit the billion-dollar mark as pharmaceutical companies have used the Orphan Drug Act to their advantage. Insurers are beginning to push back.
Projections show orphan drugs being a lucrative revenue stream for pharma for years to come, but payers are starting to scrutinize expenditures.
Despite some initially impressive results and good intentions, some wonder if this mix of altruism and capitalism can succeed.
They play a key role in the new payment models. But coordinators aren’t coordinated, and patients are getting annoyed—and worse.